[Hormonal, radiation and combined therapy of locally advanced prostatic cancer (T3NXM0)].
The analysis is presented of combined treatment of locally advanced prostatic cancer (LAPC), stage T3NXM0, in 158 LAPC patients treated in 1998-2002. The patients were divided into four groups: group 1 (n=72) received hormones in parallel with radiation, group 2 (n=52) received only hormones, group 3 (n=27) received radiotherapy after failure of long-term (1 year and more) hormone therapy, group 4 (n=7) was given teleradiotherapy only. 3-year recurrence-free survival in patients with LAPC showed advantage of the combined treatment (82 +/- 0.1%) vs hormone (56 +/- 0.1%) or radiation (69.3 +/- 0.1%) therapy alone. It provides a high local control over the primary tumor and an increase of survival, prolongs distant metastases free period, improves the patients' quality of life and their adaptation.
Pavlov
A S
AS
Loran
O B
OB
Simakina
E P
EP
Tomkevich
B A
BA
Repina
A G
AG
Gribova
R G
RG
D000368:Aged; D000369:Aged, 80 and over; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D003131:Combined Modality Therapy; D006728:Hormones / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D011471:Prostatic Neoplasms / Q000188:drug therapy / Q000532:radiotherapy / Q000628:therapy*; D016896:Treatment Outcome
D000970:Antineoplastic Agents; D006728:Hormones